<DOC>
	<DOCNO>NCT01209390</DOCNO>
	<brief_summary>The objective post-marketing study confirm clinical efficacy safety outcome treatment ChondroMimetic patient population within propose indication ( osteochondral cartilage defect ) , 36 month post-implantation follow-up period . The primary objective collect post-marketing safety data real life set mean ( S ) ADR reporting . The secondary objective : - Clinical outcome assess patient report EuroQoL-5D - Structural repair assess MRI - The number treatment failure time treatment failure - The ease use ChondroMimetic report surgeon</brief_summary>
	<brief_title>A Prospective , Post-marketing Registry Use ChondroMimetic Repair Osteochondral Defects</brief_title>
	<detailed_description />
	<mesh_term>Osteochondrosis</mesh_term>
	<criteria>1 . Signed patient inform consent 2 . Shallow osteochondral defect ≤ 12 mm diameter ≤ 8 mm depth weight bear area 3 . Agree actively participate rehabilitation protocol 1 . Severe vascular neurological disease 2 . Uncontrolled diabetes 3 . Severe degenerative joint disease 4 . Pregnancy 5 . Presence infection site joint space ( e.g . osteomyelitis ) 6 . Diagnosis rheumatoidism 7 . Advanced osteoarthritis judge surgeon 8 . Drug and/or alcohol abuse 9 . Hypercalcemia 10 . Known allergy component device ( e.g . bovine collagen ) 11 . Bleeding disorder etiology 12 . Steroidal immunosuppressive maintenance therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>osteochondral</keyword>
	<keyword>regenerative</keyword>
	<keyword>repair</keyword>
	<keyword>cartilage lesion</keyword>
</DOC>